The key Medical Affairs meeting in the EMEA region – the MAPS (Medical Affairs Professional Society) 2024 EMEA Annual Meeting took place this year from 12-14 May in Madrid. Over 400 Medical Affairs professionals from healthcare companies, patient advocacy groups, specialized consultancies and public institutions came together for 3 days to share best practices, discuss future trends in the dynamic healthcare landscape, and to jointly refine the core capabilities needed in the Medical Affairs function of the future in global and local teams. The rapidly growing number of conference attendees reflects the increasing importance and recognition of Medical Affairs.
This year, the conference theme was “From Action to Impact” to shift the attention to the actual value Medical Affairs can generate in their critical role to bridge the gap between science and clinical practice, and to improve the care for patients. Put in practice, moving from action to impact means to “start with the end in mind”: Medical Affairs first defines the desired impact and outcomes based on their strategic imperatives and only thereafter the corresponding tactics – not the other way around.
A best practice for Medical Affairs in doing that is to co-create the desired impact together with external stakeholders (e.g., HCPs and patients) who can help contextualize what is considered to be meaningful impact. Priority is given to outcomes that are both meaningful for stakeholders and at the same time realistically achievable with the available resources. Ideally, Medical Affairs activities impact the behavior, knowledge, and/or beliefs of healthcare stakeholders to drive better patient outcomes.
A key element in shifting the attention from action towards the impact and value of Medical Affairs is the systematic assessment of their impact. Quantifying the impact of Medical Affairs initiatives is essential to optimize strategies, improve execution of tactics, and demonstrate value within the healthcare space. However, despite the importance of quantifying impact, there are challenges associated with how impact is measured.
It has been widely recognized that there is a lack of standardized metrics and benchmarks for measuring the impact of Medical Affairs globally. For example, a recent 2023 MAPS Metrics Benchmark survey identified that 70% of respondents (including representatives from pharma, biotech, medical devices/diagnostic companies) did not have methodology in place to analyze the relationship between Medical Affairs activities and their overall outcomes. This suggests Medical Affairs may not be capturing their full value and impact. Furthermore, having a streamlined methodology in place to systematically assess the relationship between activities and outcomes may also identify opportunities for improvement, fuel performance, and drive Medical Affairs’ growth within the organization.
While demonstrating the impact and value of Medical Affairs poses an inherent challenge, it is worth the effort to tackle this challenge for any Medical Affairs function. Although each use case and each Medical Affairs organization is unique (and therefore require a customized measurement approach), well-defined best practices exist. These best practices can guide the successful development and implementation of meaningful metrics in practice.
The importance and recognition of Medical Affairs as a strategic partner for both internal and external stakeholders has significantly evolved over the past years and will continue to do so. To be able to demonstrate the value of Medical Affairs, systematically measuring impact is imperative. While more difficult to measure, selecting metrics that measure changes in knowledge, competence, and patient outcomes have the most utility in demonstrating the true value of Medical Affairs. (see Figure 1).
Figure 1: Illustrative Hierarchy of Medical Affairs Metrics
References:
Jump to a slide with the slide dots.
Health equity in pharma: Addressing disparities via diversity in trials, access to care, RWE, tech innovation, and cross-functional collaboration.
Read moreIntroduction The 2024 American Society of Hematology (ASH) Annual Meeting presented a wealth of data, unveiling the...
Read morePutnam shares key questions to consider in preparation of advancing trials and deals that have been put on hold.
Read more